ELVN (Enliven Therapeutics) FCF Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELVN Enliven Therapeutics Inc ELVN
31 GF Score
Price $57.89
! 3 Warning Signs
View Full Analysis

What is Enliven Therapeutics FCF Margin %?

Enliven Therapeutics ELVN -1.43% 31 FCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates ELVN with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Enliven Therapeutics ranks worse than 104821.7% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Enliven Therapeutics's Free Cash Flow for the three months ended in Jun. 2026 was $-18.53 Mil. Enliven Therapeutics's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Enliven Therapeutics's FCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.

As of today, Enliven Therapeutics's current FCF Yield % is -1.58%.

The historical rank and industry rank for Enliven Therapeutics's FCF Margin % or its related term are showing as below:


ELVN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -77.885
* Ranked among companies with meaningful FCF Margin % only.

Enliven Therapeutics FCF Margin % Related Terms

Enliven Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Enliven Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enliven Therapeutics FCF Margin % Chart

Enliven Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Enliven Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ELVN vs PBLS, CPRX, DNLI: FCF Margin % Comparison

For the Biotechnology subindustry, Enliven Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enliven Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Enliven Therapeutics's FCF Margin % falls into.


ELVN
31GF Score
Enliven Therapeutics Inc ELVN
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enliven Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Enliven Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-70.459/0
= %

Enliven Therapeutics's FCF Margin for the quarter that ended in Jun. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-18.531/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Enliven Therapeutics (ELVN) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Enliven Therapeutics and its competitors. According to the industry distribution chart, Enliven Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry.
Is Enliven Therapeutics' FCF Margin % too high?
Enliven Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Enliven Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Enliven Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enliven Therapeutics' FCF Margin % compare to PBLS and CPRX?
According to the Biotechnology industry distribution chart, Enliven Therapeutics ranks #999999 out of 954 companies for FCF Margin %. This places Enliven Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Enliven Therapeutics and its competitors. Enliven Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enliven Therapeutics stock overvalued right now?
Enliven Therapeutics (ELVN) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Enliven Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Enliven Therapeutics (ELVN), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enliven Therapeutics Business Description

Address 6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
31GF Score

Get the complete analysis for ELVN

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.89
Price